Two phase 3, placebo-controlled studies suggest the oral Janus kinase (JAK) inhibitor upadacitinib is effective for moderate-to-severe atopic dermatitis (AD),
A childhood diagnosis of atopic dermatitis was associated with lower attainment of secondary education but not higher education, according to a population-based
Exposure to antibiotics in utero and during the first year of life is associated with an increased risk for atopic
April 12, 2021 Keshav Patel, MS4 , Bernard A Cohen, MD Contemporary PEDS Journal, Vol 38 No 4, Volume 38,
Copyright © 2025, A4M. All trademarks, registered or unregistered, are the property of their respective owners.
